Mohammed Majrashi

Dr. Mohammed Majrashi

University of Jeddah, Jeddah, Makkah al Mukarramah, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Polymers
Verified
Journal Article
Open access
PDF file
RJRENATHA JIFFRIN
RENATHA JIFFRIN
Saiful Izwan Abd RazakSaiful Izwan Abd Razak
Saiful Izwan Abd Razak
Mohamad Ikhwan JamaludinMohamad Ikhwan Jamaludin
Mohamad Ikhwan Jamaludin
ASAmir Syahir
Amir Syahir
MMMuadz Ahmad Mazian
Muadz Ahmad Mazian
AAAbul Azad
Abul Azad
A medication’s approximate release profile should be sustained in order to generate the desired therapeutic effect. The drug’s release site, duration, and rate must all be adjusted to the drug’s therapeutic aim. However, when designing drug delivery systems, this may be a considerable hurdle. Electrospinning is a promising method of creating a nanofibrous membrane since it enables drugs to be placed in the nanofiber composite and released over time. Nanofiber composites designed through electrospinning for drug release purposes are commonly constructed of simple structures. This nanofiber composite produces matrices with nanoscale fiber structure, large surface area to volume ratio, and a high porosity with small pore size. The nanofiber composite’s large surface area to volume ratio can aid with cell binding and multiplication, drug loading, and mass transfer processes. The nanofiber composite acts as a container for drugs that can be customized to a wide range of drug release kinetics. Drugs may be electrospun after being dissolved or dispersed in the polymer solution, or they can be physically or chemically bound to the nanofiber surface. The composition and internal structure of the nanofibers are crucial for medicine release patterns.

18 June 2019 in Toxicology Mechanisms and Methods
Verified
Journal Article
Closed access
AAAhmad H. Alhowail
Ahmad H. Alhowail
JBJenna Bloemer
Jenna Bloemer
MMMohammed Majrashi
Mohammed Majrashi
PPPriyanka D. Pinky
Priyanka D. Pinky
SBSubhrajit Bhattacharya
Subhrajit Bhattacharya
VSVishnu Suppiramaniam
Vishnu Suppiramaniam
Cognitive deficits are commonly reported by patients following treatment with chemotherapeutic agents. Anthracycline-containing chemotherapy regimens are associated with cognitive impairment and reductions in neuronal connectivity in cancer survivors, and doxorubicin is a commonly used anthracycline. Although it has been reported that doxorubicin distribution to the central nervous system is limited, considerable doxorubicin concentrations are observed in the brain with co-administration of certain medications. Additionally, pro-inflammatory cytokines, which are overproduced in cancer or in response to chemotherapy, can reduce the integrity of the blood brain barrier. Therefore, the aim of this study was to evaluate the acute neurotoxic effects of doxorubicin on hippocampal neurons. In the current study, we utilized a hippocampal cell line (H19-7/IGF-IR) along with rodent hippocampal slices to evaluate the acute neurotoxic effects of doxorubicin. Hippocampal slices were used to measure long-term potentiation, and expression of proteins was determined by immunoblotting. Cellular assays for mitochondrial complex activity and lipid peroxidation were also utilized. We observed reduction in long-term potentiation in hippocampal slices with doxorubicin. In addition, lipid peroxidation was increased as measured by thiobarbituric acid reactive substances content indicating oxidative stress. Caspase-3 expression was increased indicating an increased propensity for cell death. Finally, the phosphorylation of signaling molecules which modulate long-term potentiation including extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, and Akt were increased. This data indicates that acute doxorubicin exposure dose-dependently impairs synaptic processes associated with hippocampal neurotransmission, induces apoptosis, and increases lipid peroxidation leading to neurotoxicity.

11 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSindhu Ramesh
Sindhu Ramesh
MGManoj Govindarajulu
Manoj Govindarajulu
TLTyler Lynd
Tyler Lynd
GBGwyneth Briggs
Gwyneth Briggs
DADanielle Adamek
Danielle Adamek
MDMuralikrishnan Dhanasekaran
Muralikrishnan Dhanasekaran
Honokiol (poly-phenolic lignan from Magnolia grandiflora) is a Sirtuin-3 (SIRT3) activator which exhibit antioxidant activity and augment mitochondrial functions in several experimental models. Modern evidence suggests the critical role of SIRT3 in the progression of several metabolic and neurodegenerative diseases. Amyloid beta (Aβ), the precursor to extracellular senile plaques, accumulates in the brains of patients with Alzheimer’s disease (AD) and is related to the development of cognitive impairment and neuronal cell death. Aβ is generated from amyloid-β precursor protein (APP) through sequential cleavages, first by β-secretase and then by γ-secretase. Drugs modulating this pathway are believed to be one of the most promising strategies for AD treatment. In the present study, we found that Honokiol significantly enhanced SIRT3 expression, reduced reactive oxygen species generation and lipid peroxidation, enhanced antioxidant activities, and mitochondrial function thereby reducing Aβ and sAPPβ levels in Chinese Hamster Ovarian (CHO) cells (carrying the amyloid precursor protein-APP and Presenilin PS1 mutation). Mechanistic studies revealed that Honokiol affects neither protein levels of APP nor α-secretase activity. In contrast, Honokiol increased the expression of AMPK, CREB, and PGC-1α, thereby inhibiting β-secretase activity leading to reduced Aβ levels. These results suggest that Honokiol is an activator of SIRT3 capable of improving antioxidant activity, mitochondrial energy regulation, while decreasing Aβ, thereby indicating it to be a lead compound for AD drug development.

1 December 2019 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
MLMadhukar Lohani
Madhukar Lohani
MMMohammed Majrashi
Mohammed Majrashi
MGManoj Govindarajulu
Manoj Govindarajulu
MPMansi Patel
Mansi Patel
SRSindhu Ramesh
Sindhu Ramesh
MDMuralikrishnan Dhanasekaran
Muralikrishnan Dhanasekaran

7 September 2023 in Heliyon
Verified
Journal Article
Open access
MAMuhammad Abubakr
Muhammad Abubakr
GAGhulam Abbas
Ghulam Abbas
SSshahid shah
shahid shah
ARAkhtar Rasul
Akhtar Rasul
Muhammad IrfanMuhammad Irfan
Muhammad Irfan
MHMuhammad Hanif
Muhammad Hanif
The present work aimed to develop nanoparticles of tobramycin (TRM) using thiolated chitosan (TCS) in order to improve the mucoadhesion, antibacterial effect and pharmacokinetics. The nanoparticles were evaluated for their compatibility, thermal stability, particle size, zeta potential, mucoadhesion, drug release, kinetics of TRM release, corneal permeation, toxicity and ocular irritation. The thiolation of chitosan was confirmed by 1H NMR and FTIR, which showed peaks at 6.6 ppm and 1230 cm−1, respectively. The nanoparticles had a diameter of 73 nm, a negative zeta potential (−21 mV) and a polydispersity index of 0.15. The optimized formulation, NT8, exhibited the highest values of mucoadhesion (7.8 ± 0.541h), drug loading (87.45 ± 1.309%), entrapment efficiency (92.34 ± 2.671%), TRM release (>90%) and corneal permeation (85.56%). The release pattern of TRM from the developed formulations was fickian diffusion. TRM-loaded nanoparticles showed good antibacterial activity against Pseudomonas aeruginosa. The optimized formulation NT8 (0.1% TRM) greatly increased the AUC(0-∞) (1.5-fold) while significantly reducing the clearance (5-fold) compared to 0.3% TRM. Pharmacokinetic parameters indicated improved ocular retention and bioavailability of TRM loaded nanoparticles. Our study demonstrated that the TRM-loaded nanoparticles had improved mucoadhesion and pharmacokinetics and a suitable candidate for effective treatment of ocular bacterial infections.

28 November 2022 in Polymers
Verified
Journal Article
Open access
PDF file
RBRana Bakhaidar
Rana Bakhaidar
NNNimbagal Raghavendra Naveen
Nimbagal Raghavendra Naveen
Pratap BasimPratap Basim
Pratap Basim
SMSamar S.A. Murshid
Samar S.A. Murshid
MKMallesh Kurakula
Mallesh Kurakula
RARayan Ahmed
Rayan Ahmed
In oral administration systems, mucoadhesive polymers are crucial for drug localization and target-specific activities. The current work focuses on the application of thiolated xanthan gum (TXG) to develop and characterize a novel mucoadhesive nanocrystal (NC) system of simvastatin (SIM). Preparation of SIM-NC was optimized using response surface methodology (RSM) coupled with statistical applications. The concentration of Pluronic F-127 and vacuum pressure were optimized by central composite design. Based on this desirable approach, the prerequisites of the optimum formulation can be achieved by a formulation having 92.568 mg of F-127 and 77.85 mbar vacuum pressure to result in EE of 88.8747% and PS of 0.137.835 nm. An optimized formulation was prepared with the above conditions along with xanthan gum (XG) and TXG and various parameters were evaluated. A formulation containing TXG showed 98.25% of SIM at the end of 96 h. Regarding the mucoadhesion potential evaluated by measuring zeta potential, TXG-SIM-NC shoed the maximum zeta potential of 16,455.8 ± 869 mV at the end of 6 h. The cell viability percentage of TXG-SIM-NC (52.54 ± 3.4% with concentration of 50 µg/mL) was less than the plain SIM, with XG-SIM-NC showing the highest cytotoxicity on HSC-3 cells. In vivo pharmacokinetic studies confirm the enhanced bioavailability of formulated mucoadhesive systems of SIM-NC, with TXG-SIM-NC exhibiting the maximum.